Literature DB >> 20590803

Craniocervical dystonia: clinical and pathophysiological features.

C Colosimo1, A Suppa, G Fabbrini, M Bologna, A Berardelli.   

Abstract

Blepharospasm, oromandibular, lingual, laryngeal and cervical dystonia are common forms of adult-onset dystonia. Each condition may appear in isolation or manifest along with other forms of craniocervical dystonia. Although the various craniocervical dystonias typically present with involuntary muscle spasms causing abnormal postures, they differ for some clinical features. Neurophysiologic and neuroimaging studies have shown a number of motor and sensory abnormalities at cortical and subcortical levels, probably reflecting a dysfunction in the basal ganglia-thalamo-cortical circuits. The best treatment for craniocervical dystonia is botulinum toxin injected into the overactive muscles.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20590803     DOI: 10.1111/j.1468-1331.2010.03045.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  20 in total

1.  Long-Term Abobotulinumtoxin A Treatment of Cervical Dystonia.

Authors:  A R Bentivoglio; E Di Stasio; D Mulas; M L Cerbarano; T Ialongo; A Laurienzo; Martina Petracca
Journal:  Neurotox Res       Date:  2017-05-06       Impact factor: 3.911

2.  Clinical outcomes of individualized botulinum neurotoxin type A injection techniques in patients with essential blepharospasm.

Authors:  Youngje Sung; Sang Min Nam; Helen Lew
Journal:  Korean J Ophthalmol       Date:  2015-03-17

Review 3.  Efficacy and safety of long-term botulinum toxin treatment in craniocervical dystonia: a systematic review.

Authors:  Carlo Colosimo; Dorina Tiple; Alfredo Berardelli
Journal:  Neurotox Res       Date:  2012-02-23       Impact factor: 3.911

Review 4.  Movement disorders of the mouth: a review of the common phenomenologies.

Authors:  C M Ghadery; L V Kalia; B S Connolly
Journal:  J Neurol       Date:  2022-07-29       Impact factor: 6.682

5.  Dementia with lewy bodies in meige syndrome.

Authors:  Lap Kei Chan; Ho Yin Ho; Chi Shing Yu
Journal:  Innov Clin Neurosci       Date:  2012-07

6.  A de novo nonsense PDGFB mutation causing idiopathic basal ganglia calcification with laryngeal dystonia.

Authors:  Gaël Nicolas; Agnès Jacquin; Christel Thauvin-Robinet; Anne Rovelet-Lecrux; Olivier Rouaud; Cyril Pottier; Marie-Hélène Aubriot-Lorton; Stéphane Rousseau; David Wallon; Christian Duvillard; Yannick Béjot; Thierry Frébourg; Maurice Giroud; Dominique Campion; Didier Hannequin
Journal:  Eur J Hum Genet       Date:  2014-02-12       Impact factor: 4.246

7.  White Matter Microstructure in Idiopathic Craniocervical Dystonia.

Authors:  Giordanna L S Pinheiro; Rachel P Guimarães; Luiza G Piovesana; Brunno M Campos; Lidiane S Campos; Paula C Azevedo; Fabio R Torres; Augusto C Amato-Filho; Marcondes C França; Iscia Lopes-Cendes; Fernando Cendes; Anelyssa D'Abreu
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2015-05-28

8.  Sudden onset of oromandibular dystonia after cerebellar stroke.

Authors:  Alper Akin; Rezzak Yilmaz; Ferda Selcuk; M Cenk Akbostancı
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2014-10-28

9.  Diffuse decreased gray matter in patients with idiopathic craniocervical dystonia: a voxel-based morphometry study.

Authors:  Camila C Piccinin; Luiza G Piovesana; Maria C A Santos; Rachel P Guimarães; Brunno M De Campos; Thiago J R Rezende; Lidiane S Campos; Fabio R Torres; Augusto C Amato-Filho; Marcondes C França; Iscia Lopes-Cendes; Fernando Cendes; Anelyssa D'Abreu
Journal:  Front Neurol       Date:  2015-01-08       Impact factor: 4.003

Review 10.  Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement.

Authors:  Alberto Albanese; Giovanni Abbruzzese; Dirk Dressler; Wojciech Duzynski; Svetlana Khatkova; Maria Jose Marti; Pablo Mir; Cesare Montecucco; Elena Moro; Michaela Pinter; Maja Relja; Emmanuel Roze; Inger Marie Skogseid; Sofiya Timerbaeva; Charalampos Tzoulis
Journal:  J Neurol       Date:  2015-04-01       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.